Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC9V for prevention of invasive extraintestinal pathogenic Escherichia coli disease in older adults
CTR20231427Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ExPEC9V in extraintestinal pathogenic Escherichia coli infection, urinary tract infection (UTI), pyelonephritis, Bacteremia, sepsis, sponsored by Janssen Pharmaceutical. Started May 2023; status: terminated.
02
Drugs
ExPEC9V
03
Conditions
extraintestinal pathogenic Escherichia coli infectionurinary tract infection (UTI)pyelonephritisBacteremiasepsis
Beyond the preview
Go deeper on CTR20231427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231427.